Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life

INTRODUCTION: Sodium glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) protect type 2 diabetic (T2D) patients from cardiovascular events, but no trial has directly compared their cardiovascular effects. We aimed to address this gap using real-world d...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMJ Open Diabetes Res Care
Главные авторы: Longato, Enrico, Di Camillo, Barbara, Sparacino, Giovanni, Gubian, Lorenzo, Avogaro, Angelo, Fadini, Gian Paolo
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Cardiovascular and Metabolic Risk
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319723/
https://ncbi.nlm.nih.gov/pubmed/32591373
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2020-001451
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы